Olema Pharmaceuticals OLMA 深 沪
交易中 05-19 11:17:52 美东时间
13.08
+0.180
+1.40%
华盛通- 最 高13.13
- 今 开12.81
- 成交量 39.00万股
- 最 低 12.63
- 昨 收 12.90
- 总市值 11.43亿
- 52周最高 36.2591
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 3.89
- 委 比 49.30%
- 总股本 8734.75万
- 历史最高 60.27
- 量 比 1.04
- 振 幅 3.88%
- 历史最低 2.00
- 每 手 1
- 风险率 8.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35
Guggenheim analyst Brad Canino maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $35.
05-13 21:48
Olema Pharmaceuticals shares are trading lower. The company reported Q1 EPS results.
Olema Pharmaceuticals shares are trading lower. The company reported Q1 EPS res...
05-13 00:46
Olema Pharmaceuticals Q1 EPS $(0.52) Beats $(0.53) Estimate
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.53) by 1.89 percent. This is a 44.44 percent decrease over losses of $(0.36) per share
05-12 19:44
Olema Pharmaceuticals Signs New Headquarters Lease at Oyster Point
Olema Pharmaceuticals ( ($OLMA) ) has shared an update. On April 27, 2026, Olem...
05-02 06:33
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals granted stock options for 188,500 shares to four new employees under its 2022 Inducement Plan, effective April 1, 2026. The options vest over four years with a 10-year term and an exercise price of $15.12 per share.
04-02 20:30
Wolfe Research Initiates Coverage On Olema Pharmaceuticals with Peer Perform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Peer Perform rating.
03-27 19:56
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
